Report Overview

According to the deep-dive market assessment study by Growth+ Reports, the Global Leadless Cardiac Pacemaker Market was valued at US$ 106 million in 2021. The market is expected to register a CAGR of 17.9% from 2022 to 2030.

Market Fundamentals

A pacemaker is a small device in the heart which sends an impulse to the heart to maintain the heartbeats or to stimuli. A leadless pacemaker is a tiny battery-powered self-contained device implanted in the heart's right ventricle. The plus generators, electrode system, and other pacemaker parts are contained in a single capsule. The leadless pacemakers are used in patients with permanent atrial fibrillation with bradycardia, sinus node dysfunction and atrioventricular block. Leadless pacemakers require a less invasive procedure, wherein a femoral vein transcatheter approach is used to place the device in the heart. 

[98748953]

Market Dynamics 

The rise in the prevalence of cardiovascular diseases and the rising geriatric population

n are the major driving factors of the global leadless cardiac pacemaker market. Moreover, the complication related to a leadless pacemaker is less compared to the traditional pacemaker, such as pocket infections, hematoma, lead dislodgment, and lead fracture. The rising demand for minimally invasive cardiac procedures over open surgeries due to shorter hospital stays, lower risk of infection and bleeding, and faster recovery is fueling the market revenue growth. Furthermore, the incorporation of advanced technologies such as AI within pacemakers and increased R&D related to leadless pacemakers is also boosting the global market revenue growth. 

Additionally, leadless pacemaker are more cosmetic appeal because there is no chest incision and visible pacemaker pocket, and the size of the leadless pacemaker is smaller than transvenous pacemakers, thus there is a rise in the demand for leadless pacemakers. 

However, the high cost of the product and stringent regulations are the main restricting factors of the global leadless cardiac pacemaker market. Moreover, lack of healthcare professional with an experience with leadless pacemakers and the issue with the battery depletion is also restraining the revenue growth of the global market. 

Market Ecosystem

The global leadless cardiac pacemaker market is analyzed from three perspectives: type, condition, and region. 

Leadless Cardiac Pacemaker Market by Type 

Based on type, the global leadless cardiac pacemaker market is segmented into Micra transcatheter pacing systems, Aveir VR Leadless Pacemaker. 

The Micra transcatheter pacing system dominates the global leadless cardiac pacemaker market with the largest market share in 2021. The Micra transcatheter pacing system is implanted in the chest with a minimally invasive procedure thus, there are no scars, and the hospital time is reduced, which boosts the segment growth. The Micra transcatheter pacing system is self-contained and is 90% smaller in comparison to the traditional pacemaker, which also plays a pivotal role in segment growth. Moreover, the patients with Micra transcatheter pacing system can undergo MRI scans, thus facilitating a constant demand. Additionally, the system automatically adjusts the heart rate by sensing the changes in the body, such as physical activity and the battery of the devices is estimated to have a life of 10 to 12 years, thus propelling the demand. 

Leadless Cardiac Pacemaker Market by Condition 

[24325325]

The global leadless cardiac pacemaker market is segmented based on Condition into atrial fibrillation, sinus node dysfunction, atrioventricular block, and others. 

The atrial fibrillation segment will hold the largest market share of the global leadless cardiac pacemaker market in 2021. The dominating share of atrial fibrillation can be attributed to the rising prevalence. Atrial fibrillation is the most common type of arrhythmia globally. Moreover, the increasing geriatric population more prone to atrial fibrillation is also playing a pivotal role in the segment's revenue growth. Additionally, the rise in the consumption of alcohol and tobacco with a lack of physical activity is increasing the risk of atrial fibrillation, propelling segment revenue growth. 

Leadless Cardiac Pacemaker Market by Region

Based on region, the global leadless cardiac pacemaker market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America dominated the global leadless cardiac pacemaker market in 2021, followed by Europe. Asia Pacific market is anticipated to register the fastest CAGR during the forecast period. The rising prevalence of atrial fibrillation in the region is a significant factor driving the regional growth. According to Centers for Disease Control and Prevention (CDC), approximately 454,000 hospitalizations occur annually in the U.S. due to atrial fibrillation. Moreover, the well-developed healthcare infrastructure with good reimbursement policies boosts regional revenue growth. The presence of the major market player in the region is also anticipated to propel regional revenue growth. 

Competitive Landscape

The prominent players operating in the global leadless cardiac pacemaker market are:

• Medtronic Plc
• Abbott Laboratories Inc.
• Boston Scientific Corporation
• MicroPort Scientific Corporation
• EBR Systems

Strategic Developments

• In February 2022, Abbott announced the world's first dual-chamber leadless pacemaker system implantation as part of its AVEIR DR i2i pivotal clinical study. This technology allows regulation of the heart rate synchronously between chambers and accurate dual-chamber leadless pacing.
• In December 2021, the MODULAR ATP clinical trial was initiated to determine the safety, performance, and effectiveness of the mCRM Modular Therapy System. The mCRM System consists of two cardiac rhythm management (CRM) devices intended to work together to coordinate therapy including EMBLEM MRI Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER Modular Pacing System (MPS). This system is designed to be the first leadless pacemaker capable of delivering both bradycardia pacing support and antitachycardia pacing (ATP).

Frequently Asked Questions About This Report